Provectus Biopharmaceuticals Inc (PVCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2019 | 03-2019 | 12-2018 | 09-2018 | 06-2018 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,324 | 1,768 | 51 | 232 | 131 |
| Receivables | 293 | 604 | 595 | 2 | 975 |
| TOTAL | $1,859 | $2,644 | $1,017 | $442 | $1,379 |
| Non-Current Assets | |||||
| PPE Net | 65 | 69 | 73 | 76 | 80 |
| Intangibles | 564 | 731 | 899 | 1,067 | 1,235 |
| Other Non-Current Assets | 230 | 248 | 0 | 838 | 833 |
| TOTAL | $859 | $1,048 | $972 | $1,981 | $2,147 |
| Total Assets | $2,718 | $3,692 | $1,988 | $2,422 | $3,526 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,554 | 1,459 | 3,312 | 2,461 | 3,501 |
| TOTAL | $2,671 | $2,871 | $4,102 | $3,250 | $4,864 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 21,013 | 19,626 | 15,303 | 14,461 | 12,362 |
| TOTAL | $21,013 | $19,626 | $15,303 | $14,461 | $12,362 |
| Total Liabilities | $23,684 | $22,497 | $19,406 | $17,711 | $17,226 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 387,592 | 384,715 | 384,715 | 384,615 | 383,111 |
| Common Shares | 385 | 385 | 385 | 384 | 383 |
| Retained earnings | -230,441 | -228,264 | -226,894 | -224,706 | -223,097 |
| Other shareholders' equity | -25 | -22 | 0 | 0 | 0 |
| TOTAL | $-20,965 | $-18,804 | $-17,418 | $-15,289 | $-13,700 |
| Total Liabilities And Equity | $2,718 | $3,692 | $1,988 | $2,422 | $3,526 |